Esophageal Cancer: New Insights into a Heterogenous Disease.

about

Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer.

P2860

Q46731469-11C7110D-E273-42B2-B584-DBECBF2EF88B

P2860

Esophageal Cancer: New Insights into a Heterogenous Disease.

Item

http://www.wikidata.org/entity/Q38734003

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Esophageal Cancer: New Insights into a Heterogenous Disease.

@en

type

Item

label

Esophageal Cancer: New Insights into a Heterogenous Disease.

@en

prefLabel

Esophageal Cancer: New Insights into a Heterogenous Disease.

@en

P1476

Esophageal Cancer: New Insights into a Heterogenous Disease.

@en

P2093

Patrick Michl

http://www.w3.org/2001/XMLSchema#string

Sebastian Krug

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative chemotherapy for resectable thoracic esophageal cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus

Cancer statistics, 2016

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

P304

253-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000464130

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28384630

http://www.w3.org/2001/XMLSchema#string

Esophageal Cancer: New Insights into a Heterogenous Disease.

about

P2860

P2860

Esophageal Cancer: New Insights into a Heterogenous Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698